

Disclosure of Conflicts of Interest

The California Society of Addiction Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CSAM policy. The CSAM is committed to providing its learners with high quality CME activities with expert faculty that provide the newest information and facilitate the practical application of this information to enhance patient care. The CSAM is also committed to educate physicians on delivering culturally and linguistically appropriate care.

Unless otherwise noted, the faculty, planners, facilitators, and staff have nothing to disclose.

Name	Reported Financial Relationship
Robert Anthenelli, MD	Dr. Anthenelli has disclosed he received grants for research support from Embera Neurotherapeutics and Pfizer.
Daniel Ciccarone, MD, MPH	Dr. Ciccarone has disclosed he receive consulting fees from Arbor Pharmaceuticals
Dustin DeYoung, MD	Dr. DeYoung has disclosed he has ownership interest and received stock, stock options from BDH Pharma
David Kan, MD	Dr. Kan disclosed he received ownership interest and received stock, stock options from Bright Heart Health
Jennifer Mitchell, PhD	Dr. Mitchell disclosed that she received grants research support from MAPS and Usona
Tricia Wright, MD	Dr. Wright disclosed that she received consulting fees from McKesson
Monika Koch, MD	Dr. Koch disclosed she received shares from the Permanente Med Group
Jacqueline Tulsy, MD	Dr. Tulsy disclosed she received stock from family trust (all benefits remain in Trust) from Gilead Science and Merck, Inc.
Jeffrey DeVido, MD	Dr. DeVido disclosed he received equity shares from inheritance from Phillip Morris/Altria

Discussion of Unlabeled Use

Faculty must disclose to participants, preferably in writing through course materials, that a product is off-label for use and/or will be discussing unlabeled/unapproved drugs or devices.